UCB (OTCMKTS:UCBJY) Shares Up 6.1% – Here’s What Happened

Shares of UCB SA (OTCMKTS:UCBJY) shot up 6.1% on Wednesday. The stock traded as high as $121.16 and last traded at $121.16. Approximately 3,002 shares traded hands during trading, a decline of 93% from the average session volume of 40,709 shares. The stock had previously closed at $114.20.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on UCBJY shares. Zacks Research lowered UCB from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 16th. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, UCB currently has an average rating of “Moderate Buy”.

UCB Trading Down 2.5%

The business has a fifty day simple moving average of $120.84 and a 200 day simple moving average of $135.15.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases in neurology and immunology. The company serves patients and healthcare professionals internationally, with operations and commercial activities spanning Europe, North America and other global markets.

UCB’s neurology portfolio includes medicines such as Vimpat (lacosamide) and Briviact (brivaracetam) for epilepsy, as well as Fintepla (fenfluramine) for certain seizure disorders.